{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:22:22Z","timestamp":1787595742459,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:00:00Z","timestamp":1707004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clml.2024.02.001","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T09:13:56Z","timestamp":1707815636000},"page":"382-391.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Julio C","family":"Chavez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-1771","authenticated-orcid":false,"given":"Ariel","family":"Grajales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5815-7471","authenticated-orcid":false,"given":"Jose","family":"Sandoval-Sus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyce","family":"Turba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Nodzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angimar","family":"Uriepero-Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ammad-Ud-Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-2275","authenticated-orcid":false,"given":"Eva","family":"Sahakian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lancet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo M","family":"Sotomayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clml.2024.02.001_bib0001","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.02.001_bib0002","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017"},{"issue":"2","key":"10.1016\/j.clml.2024.02.001_bib0003","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.02.001_bib0004","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.02.001_bib0005","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2005-04-1677","article-title":"Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia","volume":"107","author":"Binet","year":"2006","journal-title":"Blood"},{"issue":"9747","key":"10.1016\/j.clml.2024.02.001_bib0006","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clml.2024.02.001_bib0007","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"9980","key":"10.1016\/j.clml.2024.02.001_bib0008","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clml.2024.02.001_bib0009","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.02.001_bib0010","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2014-03-559591","article-title":"Lenalidomide inhibits the proliferation of CLL cells via a cereblon\/p21(WAF1\/Cip1)-dependent mechanism independent of functional p53","volume":"124","author":"Fecteau","year":"2014","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2024.02.001_bib0011","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood-2014-05-578286","article-title":"How does lenalidomide target the chronic lymphocytic leukemia microenvironment?","volume":"124","author":"Kater","year":"2014","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2024.02.001_bib0012","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1002\/cncr.25983","article-title":"Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia","volume":"117","author":"Lee","year":"2011","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2024.02.001_bib0013","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2013-04-495341","article-title":"Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia","volume":"122","author":"Strati","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.02.001_bib0014","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"issue":"14","key":"10.1016\/j.clml.2024.02.001_bib0015","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.clml.2024.02.001_bib0016","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1158\/1078-0432.CCR-15-2476","article-title":"Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics","volume":"22","author":"Vitale","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2024.02.001_bib0017","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.leukres.2016.05.012","article-title":"Results of a phase II study of lenalidomide and rituximab for refractory\/relapsed chronic lymphocytic leukemia","volume":"47","author":"Chavez","year":"2016","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.clml.2024.02.001_bib0018","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/leu.2009.133","article-title":"Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia","volume":"23","author":"Castro","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2024.02.001_bib0019","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1078-0432.CCR-11-2630","article-title":"Expansion of a CD8+ PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4: CD8 ratios and disease progression","volume":"18","author":"Nunes","year":"2012","journal-title":"Clinical Cancer Research"},{"issue":"26","key":"10.1016\/j.clml.2024.02.001_bib0020","doi-asserted-by":"crossref","first-page":"40558","DOI":"10.18632\/oncotarget.9941","article-title":"Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.clml.2024.02.001_bib0021","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3324\/haematol.2009.005835","article-title":"Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia","volume":"94","author":"Aue","year":"2009","journal-title":"haematologica"},{"issue":"4","key":"10.1016\/j.clml.2024.02.001_bib0022","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2141.2011.08882.x","article-title":"Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response","volume":"155","author":"Chanan-Khan","year":"2011","journal-title":"British journal of haematology"},{"issue":"15","key":"10.1016\/j.clml.2024.02.001_bib0023","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2007.13.9709","article-title":"Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia","volume":"26","author":"Andritsos","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.02.001_bib0024","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clml.2024.02.001_bib0025","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","article-title":"Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study","volume":"118","author":"Wierda","year":"2011","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.clml.2024.02.001_bib0026","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.02.001_bib0027","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.02.001_bib0028","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2010.29.8133","article-title":"Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia","volume":"29","author":"Chen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2024.02.001_bib0029","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.02.001_bib0030","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.2012.42.8623","article-title":"Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia","volume":"31","author":"Badoux","year":"2013","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2024.02.001_bib0031","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2009-09-242438","article-title":"Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway","volume":"115","author":"Lapalombella","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.02.001_bib0032","first-page":"250","article-title":"The addition of CD20 monoclonal antibody to lenalidomide improves response rate and survival in relapsed\/refractory patients with chronic lymphocytic leukemia","volume":"4","author":"Thompson","year":"2014","journal-title":"Haematologica: FERRATA STORTI FOUNDATION VIA GIUSEPPE BELLI"},{"issue":"3","key":"10.1016\/j.clml.2024.02.001_bib0033","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/10428194.2014.935369","article-title":"Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"56","author":"Costa","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"10.1016\/j.clml.2024.02.001_bib0034","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1200\/JCO.2013.51.5890","article-title":"Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium","volume":"32","author":"James","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.02.001_bib0035","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/bloodadvances.2019031336","article-title":"Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL","volume":"3","author":"Strati","year":"2019","journal-title":"Blood Advances"},{"issue":"12","key":"10.1016\/j.clml.2024.02.001_bib0036","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.3324\/haematol.2019.230805","article-title":"Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial","volume":"105","author":"Pettitt","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2024.02.001_bib0037","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"10232","key":"10.1016\/j.clml.2024.02.001_bib0038","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clml.2024.02.001_bib0039","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T13:01:57Z","timestamp":1716987717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024000600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2152265024000600"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.02.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}